Equities analysts expect Regenxbio Inc (NASDAQ:RGNX) to report earnings of ($0.71) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Regenxbio’s earnings, with the highest EPS estimate coming in at ($0.67) and the lowest estimate coming in at ($0.75). Regenxbio reported earnings of ($0.74) per share during the same quarter last year, which would indicate a positive year over year growth rate of 4.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that Regenxbio will report full-year earnings of ($2.83) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($2.80). For the next year, analysts anticipate that the company will report earnings of ($2.58) per share, with EPS estimates ranging from ($3.21) to ($1.43). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Regenxbio.
A number of research analysts have recently commented on RGNX shares. BidaskClub cut shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Raymond James Financial reissued a “buy” rating on shares of Regenxbio in a report on Friday, January 5th. Chardan Capital increased their target price on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research cut shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $40.63.
Regenxbio (RGNX) traded down $0.40 during mid-day trading on Tuesday, hitting $26.45. 222,879 shares of the stock were exchanged, compared to its average volume of 438,790. The company has a market capitalization of $823.79 and a PE ratio of -9.76. Regenxbio has a 52-week low of $16.30 and a 52-week high of $36.45.
In other news, SVP Curran Simpson sold 21,890 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $30.04, for a total value of $657,575.60. Following the completion of the transaction, the senior vice president now owns 41,390 shares of the company’s stock, valued at $1,243,355.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $31.75, for a total value of $317,500.00. Following the completion of the transaction, the insider now directly owns 108,530 shares of the company’s stock, valued at approximately $3,445,827.50. The disclosure for this sale can be found here. Insiders sold 84,000 shares of company stock valued at $2,601,996 in the last ninety days. 17.00% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas acquired a new position in shares of Regenxbio in the fourth quarter valued at approximately $302,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Regenxbio in the third quarter valued at approximately $328,000. Nomura Asset Management Co. Ltd. acquired a new position in shares of Regenxbio in the fourth quarter valued at approximately $333,000. Virtus Fund Advisers LLC acquired a new position in shares of Regenxbio in the fourth quarter valued at approximately $407,000. Finally, Voya Investment Management LLC acquired a new position in shares of Regenxbio in the second quarter valued at approximately $249,000. 66.85% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/20/brokerages-anticipate-regenxbio-inc-rgnx-will-announce-earnings-of-0-71-per-share.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Get a free copy of the Zacks research report on Regenxbio (RGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.